Brent Saunders

Brent is directly responsible for some of the most valuable consumer brands including Botox, Claritin, Coppertone, Juvéderm, Dr. Scholls, Renu Multipurpose Solution, Lumify, Miralax, BioTrue, Coolsculpting, SkinMedica, and Hydrafacial, among others.

In the past, Brent held key executive and board roles at Cisco, BridgeBio Pharma, Vesper Healthcare Acquisitions Company, The Beauty Health Company, Allergan/Actavis, Forest Laboratories, Bausch + Lomb Inc., Schering-Plough/Merck, PriceWaterhouseCoopers, Jefferson Health, Home Care Corporation, and Coventry Health Care.

At Schering-Plough, Brent played key roles which later culminated in its merger with Merck & Co. Subsequently, he steered Bausch + Lomb Inc. through significant restructuring, eventually leading to its acquisition by Valeant Pharmaceuticals. His leadership prowess continued at Forest Laboratories, which was later acquired by Actavis. After this merger, Brent helmed Actavis, which would further go on to adopt the name Allergan after acquiring the original company.